Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Papillomavirus Infections
100%
Carraguard
100%
Phase II Trial
100%
Human Papillomavirus
77%
Cervical Cancer
23%
Population Council
18%
Medical Center
18%
Bronx
18%
Cervicovaginal Lavage
18%
Albert Einstein
18%
College of Medicine
18%
Microbicides
14%
Abnormal Pap Test
14%
New Humanities
14%
Vaginal Microbicides
9%
Vaginal Swab
9%
Female Genital Tract
9%
Genital Tract
9%
Effective Combination
9%
One Year Period
9%
Efficacy Trial
9%
Public Hospitals
9%
Mechanism of Activity
9%
Antiviral Activity
9%
Placebo Groups
9%
Repeated Application
9%
Cervical Intraepithelial Neoplasia
9%
Clinical Trials
9%
Early Adoption
9%
Seminal Plasma
9%
Infection Prevention
9%
Formulation Vehicle
9%
Randomized Double-blind Placebo-controlled Study
9%
HIV Infection in Women
9%
Jacobi
9%
New York
9%
Sexually Transmitted Infection Prevention
9%
Manhattan
9%
Animal Model Study
9%
Combination Microbicide
9%
HIV Infection
9%
Further Development
9%
Shared Vision
9%
University Hospital
9%
Anti-HIV Agents
9%
Pseudovirion
9%
Vaginal Microbiota
9%
Trial Testing
9%
Persistent Human Papillomavirus Infection
5%
Pharmacology, Toxicology and Pharmaceutical Science
Papillomavirus Infection
100%
Phase II Trials
100%
Carrageenan
100%
Human Papillomavirus
77%
Antimicrobial Agent
32%
Uterine Cervix Cancer
23%
HIV
18%
Human Immunodeficiency Virus Infection
18%
Sexually Transmitted Disease
18%
Vagina Flora
9%
Antiviral Activity
9%
Clinical Trial
9%
Uterine Cervix Carcinoma in Situ
9%
Placebo-Controlled Study
9%
Anti Human Immunodeficiency Virus Agent
9%
Placebo
9%